00:03 , Apr 12, 2019 |  BC Week In Review  |  Clinical News

Allergan's modified abicipar pegol decreases intraocular inflammation

Ahead of a BLA submission to FDA this half for AMD therapy abicipar pegol, Allergan and Molecular Partners reported top-line safety data from the Phase II MAPLE trial showing that an optimized formulation of the...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:26 , Dec 21, 2018 |  BC Week In Review  |  Company News

Amgen adds stroma-targeted therapy via Molecular Partners deal

Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor antigen-targeted therapies. On Dec. 19, Amgen received exclusive,...
20:21 , Dec 19, 2018 |  BC Extra  |  Company News

Amgen adds stroma-targeted therapy via Molecular Partners deal

Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor antigen-targeted therapies. On Wednesday, Amgen received exclusive, worldwide...
16:02 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Allergan's abicipar pegol non-inferior to Lucentis, but increases inflammation

Allergan plc (NYSE:AGN) and Molecular Partners AG (SIX:MOLN) said both dosing regimens of abicipar pegol (AGN-150998) met the primary endpoint of non-inferiority to Lucentis ranibizumab in the proportion of patients with stable vision at week...
20:48 , Jul 19, 2018 |  BC Extra  |  Clinical News

Allergan's abicipar pegol non-inferior to Lucentis, but increases inflammation

Allergan plc (NYSE:AGN) and Molecular Partners AG (SIX:MOLN) said both dosing regimens of abicipar pegol (AGN-150998) met the primary endpoint of non-inferiority to Lucentis ranibizumab in the proportion of patients with stable vision at week...
16:04 , Jul 11, 2018 |  BC Innovations  |  Translation in Brief

Poisoning the stromal chalice

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells. Tumor-associated stroma,...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
22:35 , Jun 25, 2018 |  BC Extra  |  Company News

Management tracks: Nordic Nanovector, Molecular Partners

Cancer company Nordic Nanovector ASA (OSE:NANO) hired Eduardo Bravo as CEO, effective July 2. He was CEO at TiGenix N.V. (NASDAQ:TIG; Euronext:TIG). Protein therapeutics company Molecular Partners AG (SIX:MOLN) said CSO Michael Stumpp has become...